In 2023/24, health spending in the United Kingdom was ***** British pounds per capita, ranging from ***** pounds per capita in London, to ***** pounds per capita in East England.

This statistic displays the annual public healthcare spending in the United Kingdom from 2000 to 2023. The total public healthcare spending increased over the period concerned to approximately ***** British pounds per capita in 2022, the highest in the provided time interval, before slightly falling to ***** British pounds in 2023.

In the financial year 2021/22, there was a slight increase in health spending per head in every country in the UK compared to the previous year. That year, Scotland spent 3,490 British pounds per head on health, the highest amount compared to the other countries in the UK. This statistic displays the annual health expenditure per head in the United Kingdom from 2012/13 to 2021/22, by country.

BackgroundAnkylosing spondylitis (AS) is a chronic inflammatory arthritis which typically begins in early adulthood and impacts on healthcare resource utilisation and the ability to work. Previous studies examining the cost of AS have relied on patient-reported questionnaires based on recall. This study uses a combination of patient-reported and linked-routine data to examine the cost of AS in Wales, UK.MethodsParticipants in an existing AS cohort study (n = 570) completed questionnaires regarding work status, out-of-pocket expenses, visits to health professionals and disease severity. Participants gave consent for their data to be linked to routine primary and secondary care clinical datasets. Health resource costs were calculated using a bottom-up micro-costing approach. Human capital costs methods were used to estimate work productivity loss costs, particularly relating to work and early retirement. Regression analyses were used to account for age, gender, disease activity.ResultsThe total cost of AS in the UK is estimated at £19016 per patient per year, calculated to include GP attendance, administration costs and hospital costs derived from routine data records, plus patient-reported non-NHS costs, out-of-pocket AS-related expenses, early retirement, absenteeism, presenteeism and unpaid assistance costs. The majority of the cost (>80%) was as a result of work-related costs.ConclusionThe major cost of AS is as a result of loss of working hours, early retirement and unpaid carer’s time. Therefore, much of AS costs are hidden and not easy to quantify. Functional impairment is the main factor associated with increased cost of AS. Interventions which keep people in work to retirement age and reduce functional impairment would have the greatest impact on reducing costs of AS. The combination of patient-reported and linked routine data significantly enhanced the health economic analysis and this methodology that can be applied to other chronic conditions.

Crude rate of cost of admissions for alcohol-related conditions (Broad definition) per head of population.

Rationale Alcohol misuse across the UK is a significant public health problem with major health, social, and economic consequences. This indicator aims to highlight the impact of alcohol-related conditions on inpatient hospital services in England. High costs of alcohol-related admissions are indicative of poor population health and high alcohol consumption. This indicator highlights the resource implications of alcohol-related conditions and supports the arguments for local health promotion initiatives. Publication of this indicator will allow national and local cost estimates to be updated and consistently monitored going forward. This measure accounts for just one aspect of the cost of alcohol to society, but there are others such as primary care, crime, ambulatory services, and specialist treatment services as well as broader costs such as unemployment and loss of productivity.

The Government has said that everyone has a role to play in reducing the harmful use of alcohol. This indicator is one of the key contributions by the Government (and the Department of Health and Social Care) to promote measurable, evidence-based prevention activities at a local level, and supports the national ambitions to reduce harm set out in the Government's Alcohol Strategy. This ambition is part of the monitoring arrangements for the Responsibility Deal Alcohol Network. Alcohol-related admissions can be reduced through local interventions to reduce alcohol misuse and harm.

References: (1) PHE (2020) The Burden of Disease in England compared with 22 peer countries https://www.gov.uk/government/publications/global-burden-of-disease-for-england-international-comparisons/the-burden-of-disease-in-england-compared-with-22-peer-countries-executive-summary

Definition of numerator The total cost (£s) of alcohol-related admissions (Broad). Admissions to hospital where the primary diagnosis is an alcohol-related condition, or a secondary diagnosis is an alcohol-related external cause.

More specifically, hospital admissions records are identified where the admission is a finished episode [epistat = 3]; the admission is an ordinary admission, day case or maternity [classpat = 1, 2 or 5]; it is an admission episode [epiorder = 1]; the sex of the patient is valid [sex = 1 or 2]; there is a valid age at start of episode [startage between 0 and 150 or between 7001 and 7007]; the region of residence is one of the English regions, no fixed abode or unknown [resgor <= K or U or Y]; the episode end date [epiend] falls within the financial year, and an alcohol-attributable ICD10 code appears in the primary diagnosis field [diag_01] or an alcohol-related external cause code appears in any diagnosis field [diag_nn].

For each episode identified, an alcohol-attributable fraction is applied to the primary diagnosis field or an alcohol-attributable external cause code appears in one of the secondary codes based on the diagnostic codes, age group, and sex of the patient. Where there is more than one alcohol-related ICD10 code among the 20 possible diagnostic codes, the code with the largest alcohol-attributable fraction is selected; in the event of there being two or more codes with the same alcohol-attributable fraction within the same episode, the one from the lowest diagnostic position is selected. For a detailed list of all alcohol-attributable diseases, including ICD 10 codes and relative risks, see ‘Alcohol-attributable fractions for England: an update’ (2). Alcohol-related hospital admission episodes were extracted from HES according to the Broad definition and admissions flagged as either elective or non-elective based on the admission method field.

The cost of each admission episode was calculated using the National Cost Collection (published by NHS England) main schedule dataset for the corresponding financial year applied to elective and non-elective admission episodes. The healthcare resource group (HRG) was identified using the HES field SUSHRG [SUS Generated HRG], which is the SUS PbR derived HRG code at episode level. Healthcare Resource Groups (HRGs) are standard groupings of clinically similar treatments which use common levels of healthcare resource. The elective admissions were assigned an average of the elective and day-case costs. The non-electives were assigned an average of the non-elective long stay and non-elective short stay costs. Where the HRG was not available or did not match the National Reference Costs look-up table, an average elective or non-elective cost was imputed. This may result in the cost of these admissions being underestimated. For each record, the AAF was multiplied by the reference cost and the resulting values were aggregated by the required output geographies to provide numerators for the cost per capita indicator.

References: (2) PHE (2020) Alcohol-attributable fractions for England: an update https://www.gov.uk/government/publications/alcohol-attributable-fractions-for-england-an-update

Definition of denominator Mid-year population estimates.

Caveats Not all alcohol-related conditions require inpatient services, so this indicator is only one measure of the alcohol-related health problems in each local area. However, inpatient admissions are easily monitored, and this indicator provides local authorities with a routine method of monitoring the health impacts of alcohol in their local populations.

The Healthcare Resource Group cost assigned to each hospital admission is for the initial admission episode only and doesn’t include costs related to alcohol in any subsequent episodes in the hospital spell. Where the HRG was not available or did not match the National Reference Costs look-up table, an average elective or non-elective cost was imputed. This may result in the cost of these admissions being underestimated. It must be noted that the numerator is based on the financial year and the denominator on calendar mid-year population estimates, e.g., 2019/20 admission rates are constructed from admission counts for the 2019/20 financial year and mid-year population estimates for the 2020 calendar year. Data for England includes records with geography 'No fixed abode'. Alcohol-attributable fractions were not available for children. Conditions where low levels of alcohol consumption are protective (have a negative alcohol-attributable fraction) are not included in the calculation of the indicator. This does not include attendance at Accident and Emergency departments. Hospital Episode Statistics overall is well completed. However, year-on-year variations exist due to poor completion from a proportion of trusts.

Analysis has revealed significant differences across the country in the coding of cancer patients in the Hospital Episode Statistics. In particular, in some areas, regular attenders at hospital for treatments like chemotherapy and radiotherapy are being incorrectly recorded as ordinary or day-case admissions. Since cancer admissions form part of the overarching alcohol-related admission national indicators, the inconsistent recording across the country for cancer patients has some implication for these headline measures.

Cancer admissions make up approximately a quarter of the total number of alcohol-related admissions. Analysis suggests that, although most Local Authorities would remain within the same RAG group compared with the England average if cancer admissions were removed, the ranking of Local Authorities within RAG groups would be altered. We are continuing to monitor the impact of this issue and to consider ways of improving the consistency between areas. The COVID-19 pandemic had a large impact on hospital activity with a reduction in admissions in 2020 to 2021. Because of this, NHS Digital has been unable to analyse coverage (measured as the difference between expected and actual records submitted by NHS Trusts) in the normal way. There may have been issues around coverage in some areas which were not identified as a result.

In 2022, the average expenditure by the Italian National Health Service (Servizio Sanitario Nazionale, SSN) per patient affected by at least one chronic disease was approximately 679 euros. This statistic highlights differences in this figure according to the type of disease patients were suffering from. The highest amount of money per capita was spent by the SSN to fight congestive heart failure, with 1,875 euros for each patient affected by this disease. These figures take into account all the public healthcare services offered to chronic disease patients, including the costs of prescription drugs covered by public health insurance.

ObjectivesThe study aimed to assess if specialised healthcare service interventions in Wales benefit the population equitably in work commissioned by the Welsh Health Specialised Services Committee (WHSSC).ApproachThe study utilised anonymised individual-level, population-scale, routinely collected electronic health record (EHR) data held in the Secure Anonymised Information Linkage (SAIL) Databank to identify patients resident in Wales receiving specialist cardiac interventions. Measurement was undertaken of associated patient outcomes 2-years before and after the intervention (minus a 6-month clearance period on either side) by measuring events in primary care, hospital attendance, outpatient and emergency department. The analysis controlled for comorbidity (Charlson) and deprivation (Welsh Index of Multiple Deprivation), stratified by admission type (elective or emergency) and membership of top 5% post-intervention costs. Costs were estimated by multiplying events by mean person cost estimates.ResultsWe identified 5,999 percutaneous coronary interventions (PCI) and 1,640 coronary artery bypass graft (CABG) between 2014-06-01 to 2020-02-29. The ratio of emergency to elective interventions was 2.85 for PCI and 1.04 for CABG. In multivariate analysis significant associations were identified for comorbidity (OR = 1.52, CI = (1.01–2.27)), deprivation (OR = 1.34, CI = (1.03–1.76)) and rurality (OR = 0.81, CI = (0.70–0.95)) for PCI interventions, and comorbidity (OR = 1.47, CI = (1.10–1.98)) for CABG. Higher costs post-intervention were associated with increased comorbidity for PCI and CABG in the top 5% cost groups, but for PCI this was not seen outside the top 5%. For PCI, moderate cost increase was associated with increased deprivation, but the picture was more mixed following CABG interventions. For both interventions, lower costs post intervention were seen in rural locations.ConclusionWe identified and compared health outcomes for selected specialist cardiac interventions amongst patients resident in Wales, with these methods and analyses, providing a template for comparing other cardiac interventions.

Healthcare spending in the United Kingdom (UK) as a share of the gross domestic product (GDP) has increased since 1990, when it was 5.1 percent. By 2023, healthcare expenditure in the UK amounted 10.9 percent of the GDP. Health expenditure in the UK compared to Europe  In comparison to other European countries in 2022, the UK ranked fifth highest in terms of healthcare spending as a share of the GDP. Top of the list was Germany, which spent 12.7 percent of its GDP on healthcare in this year. This was followed by France and Austria, which spent 11.9 percent and 11.4 percent on health, respectively. Performance of the NHS in the UK  Individuals in the UK still regard the NHS as a world class health service and remain happy with the high level of care provided by the organization. Although waiting times have been getting worse in the A&E department over the years. The NHS has been falling behind the target that 95 percent of patients should be seen within four hours of arrival. As a result, the primary reasons for dissatisfaction with the NHS among the public are the length of time required to get a GP or hospital appointment and the lack of staff.   

In 2010 the Building Research Establishment (BRE) Trust published the results of a research project which sought to quantify the cost of people living in poor housing in England to the National Health Service. This was possible because of the availability of information from the English Housing Survey on the risk of a home incident occurring and its likely impact on health, measured through the Housing Health and Safety Rating System (HHSRS), combined with information from the NHS on treatment costs.A more recent briefing paper updates the BRE models and calculations using 2011 English Housing Survey and 2011 indicative NHS treatment costs. It also widens the definition from ‘poor housing’ to include all ‘sub-standard’ housing.The data presented here, with kind permission of the BRE and the report authors, sets out1. The number of homes across England which fall into categories of hazard, and the estimated cost to the NHS of each level of hazard in total.2. The frequency of various hazards making up 'poor housing' across England, setting out the cost to repair against potential savings to the NHS budget in the illnesses and accidents prevented in a year by doing the repairs; for example preventing falls in the bathroom by installing grab rails and non-slip surfaces.In this way the report provides a useful assessment of "payback periods" for hazards found in England's housing stock, offsetting the cost of putting the hazards right against the potential cost of treating people who have (for example) fallen in the bath; suffered excess cold or experienced excessive damp.

ObjectiveTo evaluate the cost-effectiveness of adding bedaquiline to a background regimen (BR) of drugs for multidrug-resistant tuberculosis (MDR-TB) in the United Kingdom (UK).MethodsA cohort-based Markov model was developed to estimate the incremental cost-effectiveness ratio of bedaquiline plus BR (BBR) versus BR alone (BR) in the treatment of MDR-TB, over a 10-year time horizon. A National Health Service (NHS) and personal social services perspective was considered. Cost-effectiveness was evaluated in terms of Quality-Adjusted Life Years (QALYs) and Disability-Adjusted Life Years (DALYs). Data were sourced from a phase II, placebo-controlled trial, NHS reference costs, and the literature; the US list price of bedaquiline was used and converted to pounds (£18,800). Costs and effectiveness were discounted at a rate of 3.5% per annum. Probabilistic and deterministic sensitivity analysis was conducted.ResultsThe total discounted cost per patient (pp) on BBR was £106,487, compared with £117,922 for BR. The total discounted QALYs pp were 5.16 for BBR and 4.01 for BR. The addition of bedaquiline to a BR resulted in a cost-saving of £11,434 and an additional 1.14 QALYs pp over a 10-year period, and is therefore considered to be the dominant (less costly and more effective) strategy over BR. BBR remained dominant in the majority of sensitivity analyses, with a 81% probability of being dominant versus BR in the probabilistic analysis.ConclusionsIn the UK, bedaquiline is likely to be cost-effective and cost-saving, compared with the current MDR-TB standard of care under a range of scenarios. Cost-savings over a 10-year period were realized from reductions in length of hospitalization, which offset the bedaquiline drug costs. The cost-benefit conclusions held after several sensitivity analyses, thus validating assumptions made, and suggesting that the results would hold even if the actual price of bedaquiline in the UK were higher than in the US.

This report shows average annual earnings for the following four earnings measures, provisionally showing overall figures for the NHS HCHS workforce (excluding primary care staff) in England in NHS Trusts and other core organisations in England and NHS Support Organisations and Central Bodies. Mean annual basic pay per FTE – is the mean amount of basic pay paid per 1 full-time equivalent post in a 12-month period. Mean annual earnings per person – is the mean amount paid to an individual in a 12-month period, regardless of the contracted FTE. Mean annual basic pay per person – is the mean amount of basic pay paid to an individual in a 12-month period, regardless of the contracted FTE. Mean annual non-basic pay per person – is the mean amount, over and above basic pay, paid to an individual in a 12 month period, regardless of the contracted FTE (this is further split into ten separate measures – see Appendix A for a list and descriptions) These figures are based on the most recent twelve months of data and are presented by staff group in the publication (Tables 1 & 2). This publication also includes tables which examine the non-basic pay elements in greater details (Table 3). Data are available every month from 30 September 2009 onwards. We have created a repository of the code used to produce the NHS Staff Earnings publication which is available on GitHub via the Related Links section below. Monthly NHS Workforce Statistics and monthly NHS Staff Sickness Absence reports and data relating to the General Practice workforce and the Independent Healthcare Provider workforce are also available via the Related Links below. We welcome feedback on the methodology and tables within this publication. Please email us with your comments and suggestions, clearly stating Monthly HCHS Workforce as the subject heading, via enquiries@nhsdigital.nhs.uk or 0300 303 5678.

NHS Payments to General Practice, England 2022/23 provides information on NHS payments to individual providers of general practice services in England. Figures are given for the main payment categories - which include Global Sum, Balance of PMS expenditure, Quality Outcomes Framework (QOF) and Local Incentive Schemes. It is not a record of the amount of money available for direct patient care, nor the total invested in patient care through general practice. Instead, it constitutes the majority of actual monies paid to practices for all activities and costs during the 2022/23 financial year. Payments relating to Primary Care Networks (PCNs) are included covering eight categories PCN Participation, PCN Leadership, PCN Support, PCN Workforce, PCN Care Home Premium, PCN Extended Hours Access, PCN Investment and Impact Fund and PCN Enhanced Access. The pandemic affected the way General Practice operated between 2020/21 and 2022/23 and placed additional responsibilities on GP practices for which they received additional payments. The report for 2022/23 includes three additional categories for COVID-19 related payments, COVID-19 Support and Expansion, COVID-19 Immunisation and Long Covid.

Healthcare spending in the United Kingdom (UK) has gradually increased since 2000 when it amounted to 78.5 billion British pounds. By 2021, healthcare expenditure in the UKreached a maximum of over 244 billion British pounds. This was an increase of approximately two billion British pounds on the previous year's healthcare spending. In 2023, this figure stood at almost 230 billion British pounds. Health expenditure in the UK compared to Europe In 2023, the UK spent almost 11 percent of its GDP on healthcare. In comparison to other European countries, this ranked the UK fifth in terms of health expenditure. At the op of the list was Switzerland, which spent 12 percent of its GDP on healthcare that year.  Performance of the NHS in the UK The majority of surveyed individuals in the UK regard the NHS as a world class health service and remain happy with the high level of care provided by the organization. Although waiting times have been getting worse in the A&E department over the years. The NHS has been falling behind the target that 95 percent of patients should be seen within four hours of arrival. As a result, the primary reasons for dissatisfaction with the NHS among the public are the length of time required to get a GP or hospital appointment and the lack of staff.

Context

To create this dataset, I first accessed government datasets from https://data.gov.uk/dataset/88c0ff75-0efb-4e9b-b8d5-2282eb03efb8/spend-over-25-000-in-salisbury-nhs-foundation-trust/

These datasets contained monthly records of spending in the Salisbury NHs Foundation Trust. I merged and cleaned all the datasets to produce one large CSV file.

Content

This dataset contains all details of expenditure from 2010 to 2020 by the Salisbury NHS Foundation Trust. There are a few months missing due to issues with data.gov.uk.

Acknowledgements

Our thanks to the Salisbury NHS Foundation Trust for collecting the original data.

License: Open Government License, http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/

Inspiration

This is the first open dataset for the Salisbury Open Data Project. We welcome any and every possible exploration of this data.

Hello, thank you for fulfilling my previous request at https://opendata.nhsbsa.net/dataset/foi-01426 Could I please request the same data, but for any newer months for which data is available? i.e. November and December 2023, and January 2024. Response I can confirm that the NHSBSA holds the information you have requested and a copy of the information and notes explaining it is attached. Please read the below notes to ensure correct understanding of the data. NHS Prescription Services process prescriptions for Pharmacy Contractors, Appliance Contractors, Dispensing Doctors and Personal Administration with information then used to make payments to pharmacists and appliance contractors in England for prescriptions dispensed in primary care settings (other arrangements are in place for making payments to Dispensing Doctors and Personal Administration). This involves processing over 1 billion prescription items and payments totalling over £9 billion each year. The information gathered from this process is then used to provide information on costs and trends in prescribing in England and Wales to over 25,000 registered NHS and Department of Health and Social Care users. Data source Source System – Insight Data Warehouse. Time period November-December 2023, and January-February 2024 for the Pharmacy Contractor file January 2024-March 2024 for the Appliance Contractor file This dataset FOI 01916 has 7 files November-December 2023, and January-February 2024 for the Pharmacy Contractor file, January 2024-March 2024 for the Appliance Contractor file. This report consists of a management information file detailing monthly Community Pharmacy and Appliance Payments by type of payment and contractor account. Payments include all drug costs, fees, patient charges, locally authorised payments, etc. Other details such as the numbers of items dispensed, and patient charges collected are also included. The management information file reflects the contractor's payment and prescription data associated with the Integrated Care Boards (ICBs) structure at the relevant payment date. Disclosure Control The data in columns ‘METHADONE PAYMENT FEE’ and ‘CONTROLLED DRUGS FEE VALUE’ within the Pharmacy dataset have been removed following Information Governance policy.

There is a Data Dictionary describing each column of data once you select a time period (at the bottom of the screen) Dataset: Prescription Cost Analysis (PCA) Monthly Administrative Data https://opendata.nhsbsa.net/dataset/prescription-cost-analysis-pca-monthly-data You can download BNF information from the Information Services Portal (ISP) to filter the above spreadsheets by the BNF code you are looking for. https://applications.nhsbsa.nhs.uk/infosystems/welcome This can be found under +Data, then Drug Data, then BNF Code Information. For information on English prescribing data issued in England and dispensed in England, Wales, Scotland, Guernsey, Alderney, Jersey, and the Isle of Man.